

## Electronic supplementary material for

### A bimodal fluorescence-Raman probe for cellular imaging

Jiarun Lin <sup>1,2</sup>, Marcus E. Graziotto <sup>1</sup>, Peter A. Lay <sup>1,2,3\*</sup> and Elizabeth J. New <sup>1,2,4\*</sup>

1 School of Chemistry, The University of Sydney, NSW 2006, Australia; jiarun.lin@sydney.edu.au (J.L.); marcus.graziotto@sydney.edu.au (M.E.G.)

2 The University of Sydney Nano Institute (Sydney Nano), The University of Sydney, NSW 2006, Australia

3 Sydney Analytical, The University of Sydney, Sydney, NSW 2006, Australia

4 Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, NSW 2006, Australia

\* Correspondence: +61 2 9351 4269, peter.lay@sydney.edu.au (P.A.L.); + 61 2 9351 3329, elizabeth.new@sydney.edu.au (E.J.N.)

#### Cell viability assays

Cell viability was determined using the MTT assay, making use of the conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to an insoluble purple formazan product by the mitochondrial dehydrogenase of viable cells. The insoluble product can be quantified spectrophotometrically upon dissolution in a suitable solvent.

3T3-L1 preadipocyte cells were seeded in each well of flat-bottomed plastic 96-well plates (Corning) and differentiated as described in the methods. **NpCN1** solutions were added to quintuplicate wells to give final concentrations ranging from 0 – 100  $\mu$ M. Following 24 h incubation, MTT (0.5 mg/mL) was added to each well, and the plates were incubated for an additional 4 h. The culture medium was removed, and DMSO (110  $\mu$ L) was added. The plates were shaken for 10 seconds and the absorbance measured immediately at 600 nm in a PerkinElmer EnSpire Plate Reader (PerkinElmer, Inc.). Values were normalised to controls containing maintenance media only.


#### General synthesis and characterisation

Reactions were performed under a nitrogen atmosphere unless otherwise indicated. Anhydrous 1,4-dioxane was obtained from Sigma Aldrich. Peptide-grade *N,N*-dimethylformamide (DMF) was obtained from LabScan. All other reagents and solvents were used as supplied unless indicated. Reactions were monitored by silica gel thin-layer chromatography plates (Merck, TLC Silica gel 60 F<sub>254</sub>). Column chromatography was performed on silica gel 60 (Merck, 0.040-0.063 mm) or using a Biotage Isolera One. Preparative thin layer chromatography was performed on silica gel 60 glass preparative plates (Yucheng Chemical (Shanghai) Co. Ltd, 1 mm thick, 20 × 20 cm).

All NMR spectra were obtained at 300 K on Bruker AVANCE III 400 or Bruker AVANCE III 500 spectrometers equipped with a 5 mm BBFO probe with z-gradients. Deuterated CDCl<sub>3</sub> were obtained from Cambridge Isotope Laboratories. All chemical shifts are reported in ppm and all coupling constants are reported in Hz. <sup>1</sup>H NMR spectra are calibrated to trace isotopic impurities of the solvent ( $\delta$  = 7.26 ppm for CDCl<sub>3</sub>). <sup>1</sup>H NMR data are reported as: chemical shift, multiplicity, coupling constant(s) (*J*) and relative integral. The multiplicities are reported as one or more of the following: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, m = multiplet, br = broad. <sup>13</sup>C{<sup>1</sup>H} NMR spectra are calibrated to trace isotopic impurities of the solvent ( $\delta$  = 77.16 ppm for CDCl<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR data is reported as chemical shift.

Low resolution ESI and APCI mass spectrometry was performed on a Bruker AmaZon SL ion trap mass spectrometer. For low resolution ESI, samples were injected via flow injection at 0.3 mL/min in methanol or acetonitrile into an Apollo II source with nitrogen drying gas at 180 °C. For low resolution APCI, samples were placed in a melting point tube and inserted into the Bruker Apollo II APCI source with an atmospheric solid analysis probe attachment added with vaporisation temperature 400 °C and corona current 4  $\mu$ A. High resolution ESI mass spectrometry was performed on a Bruker solarix 2XR Fourier Transform Ion Cyclotron Resonance Mass Spectrometer. Samples were injected using the supplied syringe pump at 180  $\mu$ L/h with nebuliser flow 1 L/min and drying gas 4L/min at 180 °C.

## Detailed synthesis



**Scheme S1.** Synthesis of **NpCN1**.

### 4-Butylamino-*N*-butyl-1,8-naphthalimide (**1**)

4-Bromonaphthalic anhydride (1.00 g, 3.60 mmol) and  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  (0.090 g, 0.36 mmol) were suspended in absolute EtOH (30 mL). *n*-Butylamine (10 mL, 97 mmol) was added and the reaction was heated to reflux for 16 h. The reaction mixture was then poured into iced 1 M HCl (200 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  ( $3 \times 100$  mL). The organic extracts were washed with 0.1 M HCl (250 mL), dried over  $\text{Na}_2\text{SO}_4$  and concentrated *in vacuo*. The crude was dissolved in EtOAc (30 mL) and filtered through a silica plug, and the solvent was removed *in vacuo*. The residue was recrystallised from absolute EtOH to afford **1** as gold needles (0.39 g, 34%).

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.53 (dd,  $J = 7.3, 0.8$  Hz, 1H), 8.42 (d,  $J = 8.4$  Hz, 1H), 8.07 (dd,  $J = 8.4, 0.9$  Hz, 1H), 7.55 (dd,  $J = 7.4, 0.8$  Hz, 1H), 6.68 (d,  $J = 8.5$  Hz, 1H), 4.15 (t,  $J = 7.6$  Hz, 1H), 3.38 (t,  $J = 7.2$  Hz, 1H), 1.81–1.75 (m, 2H), 1.73–1.67 (m, 2H), 1.55–1.48 (m, 2H), 1.46–1.39 (m, 2H), 1.01 (t,  $J = 7.3$  Hz, 3H), 0.95 (t,  $J = 7.3$  Hz, 3H).

$^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.8, 164.2, 149.6, 134.5, 131.1, 129.9, 125.9, 124.7, 123.3, 120.3, 110.3, 104.4, 43.6, 40.1, 31.1, 30.4, 20.55, 20.46, 13.99, 13.95.

LRMS (APCI)  $m/z$ :  $[\text{M}+\text{H}]^+$  Calcd for  $\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}_2^+$  325; Found 325.

Characterisation data matches that reported in the literature.<sup>37</sup>

### 3-Bromo-4-butylamino-*N*-butyl-1,8-naphthalimide (2)

**1** (500 mg, 1.5 mmol) was dissolved in DMF (7 mL) and cooled to 0 °C. A solution of freshly-recrystallised *N*-bromosuccinimide (0.37 g, 2.1 mmol) in DMF (10 mL) was added dropwise over 1 h. The reaction was warmed to rt and stirred for 3 h. The reaction mixture was diluted with 5% LiCl solution (100 mL) and extracted with EtOAc (50 mL). The organic extract was washed with 5% LiCl solution (5 × 50 mL), dried over MgSO<sub>4</sub> and concentrated *in vacuo*. Purification by column chromatography (SiO<sub>2</sub>, 6% EtOAc in hexanes) afforded **2** (0.49 g, 79%) as a yellow powder.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.62 (s, 1H), 8.57 (d, *J* = 7.3 Hz, 1H), 8.45 (d, *J* = 8.6 Hz, 1H), 7.64 (t, *J* = 7.6 Hz, 1H), 4.15 (t, *J* = 7.6 Hz, 2H), 3.67 (t, *J* = 6.9 Hz, 2H), 1.78 – 1.64 (m, 4H), 1.53 – 1.37 (m, 4H), 0.99 – 0.94 (m, 6H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): 164.3, 163.2, 149.8, 135.6, 131.5, 130.7, 129.8, 125.3, 123.5, 123.4, 114.4, 110.0, 50.9, 40.3, 33.7, 30.6, 20.5, 20.1, 14.0, 13.9.

LRMS (APCI) *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>2</sub><sup>+</sup> 403 and 405; Found 403 and 405.

Characterisation data matches that reported in the literature.<sup>37</sup>

### 3-(3-Benzonitrile)-4-butylamino-*N*-butyl-1,8-naphthalimide (NpCN1)


**2** (0.25 g, 0.62 mmol), 3-cyanophenylboronic acid (0.18 g, 1.2 mmol), K<sub>2</sub>CO<sub>3</sub> (0.17 g, 1.2 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (36 mg, 5 mol%) were placed under an N<sub>2</sub> atmosphere. A degassed 3:1 1,4-dioxane:H<sub>2</sub>O (30 mL) mixture was added, and the reaction mixture was heated to 80 °C for 16 h. Upon completion, the reaction was diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 40 mL). The organic extracts were washed with brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. Purification by column chromatography (SiO<sub>2</sub>, 25% EtOAc in hexanes) afforded **NpCN1** (0.23 g, 88%) as a yellow powder.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.61 (dd, *J* = 7.3, 0.9 Hz, 1H), 8.34 (dd, *J* = 8.5, 0.9 Hz, 1H), 8.32 (s, 1H), 7.80–7.79 (m, 1H), 7.75–7.70 (m, 3H), 7.65–7.61 (t, *J* = 7.7 Hz, 1H), 4.58 (t, *J* = 5.0 Hz, 1H), 4.17 (t, *J* = 7.6 Hz, 2H), 3.12 (q, *J* = 6.8 Hz, 2H), 1.73–1.67 (m, 2H), 1.50–1.40 (m, 4H), 1.26–1.18 (m, 2H), 0.96 (t, *J* = 7.4 Hz, 3H), 0.82 (t, *J* = 7.4 Hz, 3H).


<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 164.5, 164.0, 149.3, 141.1, 135.3, 133.9, 133.0, 131.6, 131.5, 130.1, 129.8, 128.8, 125.7, 123.6, 123.5, 123.4, 118.5, 113.6, 113.4, 49.8, 40.2, 33.2, 30.4, 20.5, 20.0, 14.0, 13.8.


HRMS (ESI) *m/z*: [M+H]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> 426.2176; Found 426.2171.

# <sup>1</sup>H NMR of NpCN1



# <sup>13</sup>C NMR of NpCN1





**Scheme S2.** Synthesis of alkyne-tagged naphthalimide variant.

**6-bromo-2-(prop-2-yn-1-yl)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione (3)**

A solution of 4-bromo-1,8-naphthalic anhydride (3.01 g, 10.9 mmol) and propargylamine (750  $\mu$ L, 11.7 mmol, 1.1 equiv) in EtOH (100 mL) was heated at reflux at 80 °C for 16 h under an N<sub>2</sub> atmosphere. The mixture was cooled to rt and then diluted using ice-cold H<sub>2</sub>O (200 mL), with the resulting precipitate collected using vacuum filtration. Purification by column chromatography (SiO<sub>2</sub>, 30% EtOAc in hexanes) afforded **3** (2.31 g, 68%) as a white powder.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.70 (dd,  $J$  = 7.3, 1.0 Hz, 1H), 8.59 (dd,  $J$  = 8.5 Hz, 1.0, 1H), 8.45 (d,  $J$  = 7.8 Hz, 1H), 8.06 (d,  $J$  = 7.9 Hz, 1H), 7.87 (dd,  $J$  = 8.5 Hz, 7.4, 1H), 4.96 (d,  $J$  = 2.5 Hz, 2H), 2.20 (t,  $J$  = 2.5 Hz, 1H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  162.92, 162.90, 133.8, 132.5, 131.7, 131.3, 130.87, 130.86, 129.2, 128.3, 122.9, 122.0, 78.4, 70.8, 29.6.

LRMS (ESI)  $m/z$ : [M+H]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>9</sub>BrNO<sub>2</sub><sup>+</sup> 314 and 316; Found 314 and 316.

Characterisation data matches that reported in the literature.<sup>35</sup>

**2-(prop-2-yn-1-yl)-6-(propylamino)-1*H*-benzo[*de*]isoquinoline-1,3(2*H*)-dione (4)**


A solution of **3** (102 mg, 0.324 mmol) and *n*-propylamine (120  $\mu$ L, 1.46 mmol, 4.5 equiv) in DMSO (3 mL) was heated at 90 °C for 16 h under a N<sub>2</sub> atmosphere. The solution was cooled to rt and then diluted using ice-cold water (25 mL), with the resulting precipitate was collected using vacuum filtration. Purification by preparative thin layer chromatography (SiO<sub>2</sub>, 30% EtOAc in hexanes) afforded **4** (61 mg, 64%) as a yellow powder.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.60 (dd,  $J$  = 7.3, 0.9 Hz, 1H), 8.48 (d,  $J$  = 8.4 Hz, 1H), 8.09 (dd,  $J$  = 8.5, 1.0 Hz, 1H), 7.61 (dd,  $J$  = 8.3, 7.4 Hz, 1H), 6.72 (d,  $J$  = 8.5 Hz, 1H), 5.31 (br, 1H), 4.94 (d,  $J$  = 2.95 Hz, 2H), 3.39 (t,  $J$  = 6.5 Hz, 2H), 2.17 (t,  $J$  = 2.4 Hz, 1H), 1.86 (sext,  $J$  = 7.3, 2H), 1.11 (t,  $J$  = 7.4, 3H).


<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  163.9, 163.2, 149.8, 134.9, 131.4, 129.9, 126.1, 124.7, 122.9, 120.2, 109.8, 104.4, 79.2, 70.0, 45.5, 29.2, 12.3, 11.6.

LRMS (ESI)  $m/z$ : [M+H]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> 293; Found 293.


Characterisation data matches that reported in the literature.<sup>36</sup>




**Figure S1.** Raman spectrum of alkyne tagged variant **4**, in the solid state, taken with the 50X and 785 nm laser excitation.




**Figure S2.** Raw Raman spectrum of **NpCN1**, in the solid state, taken with the 50X and 785 nm laser excitation. Processed spectrum is seen in Figure 2D.




**Figure S3.** Cell viability of **NpCN1** in 3T3-L1 cells. Dotted line represents average cell viability of controls containing maintenance media only.



**Figure S4.** Bimodal cell studies of a representative fixed 3T3-L1 cell dosed with an equivalent volume of DMSO to cells dosed with **NpCN1**. (A) shows the bright field and (B) shows the confocal fluorescence image of the cell. (C) shows Raman maps with the distribution of phenylalanine (1000-1010  $\text{cm}^{-1}$ ), lipid C-C/fatty acids (1118-1138  $\text{cm}^{-1}$ ), tryptophan (1550-1560  $\text{cm}^{-1}$ ), lipid C=C (1625-1690  $\text{cm}^{-1}$ ), lipid esters (1720-1775  $\text{cm}^{-1}$ ) and **NpCN1** (2222-2242  $\text{cm}^{-1}$ ); maps obtained via calculation of the signal-to-baseline of spectra. (D) and (E) show selected spectra extracted from locations **a-f** as shown in (A). Scale bar represents 10  $\mu\text{m}$  for all images and maps.



**Figure S5.** Principal component analysis of the Raman spectra of a 3T3-L1 cell dosed with an equivalent volume of DMSO to cells dosed with **NpCN1**; cell is the same representative cell shown in Figure S4. (A) and (B) show the PC maps of each of the scores of the four main PC of the spectra collected from 715-1806  $\text{cm}^{-1}$  and 1327-2304  $\text{cm}^{-1}$  respectively. (C) and (D) show the loadings of the scores mapped in (A) and (B) respectively. Scale bar represents 10  $\mu\text{m}$  for all maps.



**Figure S6.** Confocal microscopy images of live 3T3-L1 cells treated with (A-F) NpCN1 (20  $\mu$ M, 40 min) or (G-L) Nile Red (10  $\mu$ M, 40 min). Live cells were imaged in (A,G) red ( $\lambda_{\text{ex}}$  = 561 nm,  $\lambda_{\text{em}}$  = 570-670 nm), (B,H) green ( $\lambda_{\text{ex}}$  = 488 nm,  $\lambda_{\text{em}}$  = 500-600 nm) and (C,I) blue ( $\lambda_{\text{ex}}$  = 405 nm,  $\lambda_{\text{em}}$  = 450-550 nm) channels, along with (D,J) bright field images. (E,K) shows overlay of all channels; (F) shows overlay of C and D, (L) shows overlay of H and K. Scale bar on all images represents 50  $\mu$ m.